Evidence map›Paper›PMID 35406511›Full record

ArticleCancers2022

Deep Learning Facilitates Distinguishing Histologic Subtypes of Pulmonary Neuroendocrine Tumors on Digital Whole-Slide Images.

Marius Ilié, Jonathan Benzaquen, Paul Tourniaire, Simon Heeke, Nicholas Ayache, Hervé Delingette, Elodie Long-Mira, Sandra Lassalle, Marame Hamila, Julien Fayada and 8 more

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Marius IliéLaboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.ORCID 0000-0002-2014-1236
Jonathan BenzaquenTeam 4, Institute of Research on Cancer and Aging, CNRS INSERM, Centre Antoine Lacassagne, Université Côte d'Azur, 06100 Nice, France.ORCID 0000-0002-1899-9612
Paul TourniaireEpione Team, Inria, Université Côte d'Azur, 06220 Sophia Antipolis, France.ORCID 0000-0002-0563-8711
Simon HeekeDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-5916-534X
Nicholas AyacheEpione Team, Inria, Université Côte d'Azur, 06220 Sophia Antipolis, France.
Hervé DelingetteEpione Team, Inria, Université Côte d'Azur, 06220 Sophia Antipolis, France.
Elodie Long-MiraLaboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
Sandra LassalleLaboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
Marame HamilaLaboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
Julien FayadaHospital-Related Biobank (BB-0033-00025), Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
Josiane OttoDepartment of Oncology, Antoine Lacassagne Center, Université Côte d'Azur, 06100 Nice, France.
Charlotte CohenDepartment of Thoracic Surgery, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
Abel Gomez-CaroDepartment of Thoracic Surgery, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.ORCID 0000-0001-5813-0551
Jean-Philippe BerthetTeam 4, Institute of Research on Cancer and Aging, CNRS INSERM, Centre Antoine Lacassagne, Université Côte d'Azur, 06100 Nice, France.
Charles-Hugo MarquetteTeam 4, Institute of Research on Cancer and Aging, CNRS INSERM, Centre Antoine Lacassagne, Université Côte d'Azur, 06100 Nice, France.ORCID 0000-0002-0846-9941
Véronique HofmanLaboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.
Christophe BontouxLaboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.ORCID 0000-0001-5446-6197
Paul HofmanLaboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Université Côte d'Azur, 06000 Nice, France.ORCID 0000-0003-0431-9353

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The histological distinction of lung neuroendocrine carcinoma, including small cell lung carcinoma (SCLC), large cell neuroendocrine carcinoma (LCNEC) and atypical carcinoid (AC), can be challenging in some cases, while bearing prognostic and therapeutic significance. To assist pathologists with the differentiation of histologic subtyping, we applied a deep learning classifier equipped with a convolutional neural network (CNN) to recognize lung neuroendocrine neoplasms. Slides of primary lung SCLC, LCNEC and AC were obtained from the Laboratory of Clinical and Experimental Pathology (University Hospital Nice, France). Three thoracic pathologists blindly established gold standard diagnoses. The HALO-AI module (Indica Labs, UK) trained with 18,752 image tiles extracted from 60 slides (SCLC = 20, LCNEC = 20, AC = 20 cases) was then tested on 90 slides (SCLC = 26, LCNEC = 22, AC = 13 and combined SCLC with LCNEC = 4 cases; NSCLC = 25 cases) by F1-score and accuracy. A HALO-AI correct area distribution (AD) cutoff of 50% or more was required to credit the CNN with the correct diagnosis. The tumor maps were false colored and displayed side by side to original hematoxylin and eosin slides with superimposed pathologist annotations. The trained HALO-AI yielded a mean F1-score of 0.99 (95% CI, 0.939-0.999) on the testing set. Our CNN model, providing further larger validation, has the potential to work side by side with the pathologist to accurately differentiate between the different lung neuroendocrine carcinoma in challenging cases.

Indexed as

CNNdeep learningHALO-AIlungneuroendocrine carcinoma

Identifiers

PMID35406511
PMCPMC8996915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.